Answer
Yes, therapy including Enrylaze (recombinant crisantaspase) can cause liver toxicity; bilirubin and transaminases should be monitored before treatment and as clinically required during treatment, and severe liver toxicity requires discontinuation and supportive care.
Sources for this answer
- Enrylaze 10 mg/0.5 ml Solution for injection/infusionJazz Pharmaceuticals UK Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 2Document updated
Sources checked